As issues of product consistency, standardization and specificity are being tackled, can phage therapeutics—long oversold and overhyped—finally realize their antibacterial potential?
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Dedrick, R. M. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0437-z (2019).
Thiel, K. Nat. Biotechnol. 22, 31–36 (2004).
Schooley, R. T. et al. Antimicrob. Agents Chemother. 61, e00954–17 (2017).
van Kessel, J. C. & Hatfull, G. F. Nat. Methods 4, 147–152 (2007).
Price, M. N. et al. Nature 557, 503–509 (2018).
Chan, B. K. et al. Evol. Med. Public Health 2018, 60–66 (2018).
Jault, P. et al. Lancet Infect. Dis. 19, 35–45 (2019).
Salmond, G. P. & Fineran, P. C. Nat. Rev. Microbiol. 13, 777–786 (2015).
Gomaa, A. A. MBio https://doi.org/10.1128/mBio.00928-13 (2014).
Citorik, R. J., Mimee, M. & Lu, T. K. Nat. Biotechnol. 32, 1141–1145 (2014).
Citorik, R. J. et al. Nat. Biotechnol. 32, 1141–1145 (2014).
About this article
Cite this article
Schmidt, C. Phage therapy’s latest makeover. Nat Biotechnol 37, 581–586 (2019). https://doi.org/10.1038/s41587-019-0133-z